Publication | Open Access

Dose-Limiting Pulmonary Toxicity in a Phase 1/2 Study of Radiation and Chemotherapy with Ipilimumab Followed by Nivolumab for Patients With Stage 3 Unresectable Non-Small Cell Lung Cancer

Phase 1/2Radiation MedicineOncologyIpilimumab FollowedMetronomic TherapyPharmacologyDose-limiting Pulmonary ToxicityBronchial NeoplasmPulmonary MedicineCancer TreatmentMedicineRadiation OncologyLung Cancer